{"nctId":"NCT01010932","briefTitle":"Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)","startDateStruct":{"date":"2009-10"},"conditions":["Cerebral Arterial Diseases"],"count":222,"armGroups":[{"label":"Dotarem and TOF MRA","type":"EXPERIMENTAL","interventionNames":["Drug: Dotarem","Other: TOF MRA"]}],"interventions":[{"name":"Dotarem","otherNames":["Gadoterate meglumine"]},{"name":"TOF MRA","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female, aged more than 18 years\n* Strongly suspected of having carotid or vertebral arterial disease\n* Scheduled (or to be scheduled) to undergo computed tomography angiography (CTA) examination\n\nExclusion Criteria:\n\n* Known grade IV or V chronic kidney disease (GFR\\<30 mL/min/1.73m²)\n* Contraindication to MRI\n* Acute renal dysfunction within the 6 months preceding Dotarem®-enhanced MRA examination","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Technical Failure Rate","description":"Rate of non-assessable arterial segments as measured by 3 independent readers in off-site evaluation of TOF-MRA and Dotarem-enhanced MRA (re-read DGD-44-060).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.65","spread":null},{"groupId":"OG001","value":"29.44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.77","spread":null},{"groupId":"OG001","value":"16.70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.20","spread":null},{"groupId":"OG001","value":"18.54","spread":null}]}]}]},{"type":"PRIMARY","title":"Sensitivity","description":"Rate of true stenotic segments (i.e. with stenosis \\>= 70%) of TOF and Dotarem-enhanced MRA evaluated by 3 independent off-site readers at the segment level, with CTA as standard of truth (re-read DGD-44-060).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.46","spread":null},{"groupId":"OG001","value":"53.85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.08","spread":null},{"groupId":"OG001","value":"63.08","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.85","spread":null},{"groupId":"OG001","value":"49.23","spread":null}]}]}]},{"type":"PRIMARY","title":"Specificity","description":"Rate of true non-stenotic segments (i.e. without stenosis \\>= 70%) of TOF and Dotarem-enhanced MRA evaluated by 3 independent off-site readers at the segment level, with CTA as standard of truth (re-read DGD-44-060).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.13","spread":null},{"groupId":"OG001","value":"85.43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.51","spread":null},{"groupId":"OG001","value":"90.39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.63","spread":null},{"groupId":"OG001","value":"90.42","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":200},"commonTop":["Hypertension","Injection site hematoma","Nausea","Dizziness","Headache"]}}}